271 related articles for article (PubMed ID: 1847075)
1. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II.
Robinson MJ; Osheroff N
Biochemistry; 1991 Feb; 30(7):1807-13. PubMed ID: 1847075
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide.
Robinson MJ; Osheroff N
Biochemistry; 1990 Mar; 29(10):2511-5. PubMed ID: 2159323
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.
DeVore RF; Corbett AH; Osheroff N
Cancer Res; 1992 Apr; 52(8):2156-61. PubMed ID: 1313738
[TBL] [Abstract][Full Text] [Related]
4. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide.
Osheroff N
Biochemistry; 1989 Jul; 28(15):6157-60. PubMed ID: 2551366
[TBL] [Abstract][Full Text] [Related]
5. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Robinson MJ; Corbett AH; Osheroff N
Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484
[TBL] [Abstract][Full Text] [Related]
6. Eukaryotic topoisomerase II. Characterization of enzyme turnover.
Osheroff N
J Biol Chem; 1986 Jul; 261(21):9944-50. PubMed ID: 3015913
[TBL] [Abstract][Full Text] [Related]
7. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
Bakic M; Chan D; Andersson BS; Beran M; Silberman L; Estey E; Ricketts L; Zwelling LA
Biochem Pharmacol; 1987 Dec; 36(23):4067-77. PubMed ID: 2825713
[TBL] [Abstract][Full Text] [Related]
8. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.
Robinson MJ; Martin BA; Gootz TD; McGuirk PR; Moynihan M; Sutcliffe JA; Osheroff N
J Biol Chem; 1991 Aug; 266(22):14585-92. PubMed ID: 1650363
[TBL] [Abstract][Full Text] [Related]
9. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
Corbett AH; Hong D; Osheroff N
J Biol Chem; 1993 Jul; 268(19):14394-8. PubMed ID: 8390992
[TBL] [Abstract][Full Text] [Related]
10. Effects of the DNA intercalators 4'-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage.
Pommier Y; Minford JK; Schwartz RE; Zwelling LA; Kohn KW
Biochemistry; 1985 Nov; 24(23):6410-6. PubMed ID: 3002440
[TBL] [Abstract][Full Text] [Related]
11. Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate.
Zechiedrich EL; Christiansen K; Andersen AH; Westergaard O; Osheroff N
Biochemistry; 1989 Jul; 28(15):6229-36. PubMed ID: 2551367
[TBL] [Abstract][Full Text] [Related]
12. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
13. Effect of casein kinase II-mediated phosphorylation on the catalytic cycle of topoisomerase II. Regulation of enzyme activity by enhancement of ATP hydrolysis.
Corbett AH; DeVore RF; Osheroff N
J Biol Chem; 1992 Oct; 267(28):20513-8. PubMed ID: 1328202
[TBL] [Abstract][Full Text] [Related]
14. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
Adlakha RC; Ashorn CL; Chan D; Zwelling LA
Cancer Res; 1989 Apr; 49(8):2052-8. PubMed ID: 2539251
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
Zwelling LA; Mayes J; Hinds M; Chan D; Altschuler E; Carroll B; Parker E; Deisseroth K; Radcliffe A; Seligman M
Biochemistry; 1991 Apr; 30(16):4048-55. PubMed ID: 1850298
[TBL] [Abstract][Full Text] [Related]
16. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
17. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events.
Sørensen BS; Sinding J; Andersen AH; Alsner J; Jensen PB; Westergaard O
J Mol Biol; 1992 Dec; 228(3):778-86. PubMed ID: 1335085
[TBL] [Abstract][Full Text] [Related]
18. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
19. A role for the passage helix in the DNA cleavage reaction of eukaryotic topoisomerase II. A two-site model for enzyme-mediated DNA cleavage.
Corbett AH; Zechiedrich EL; Osheroff N
J Biol Chem; 1992 Jan; 267(2):683-6. PubMed ID: 1309770
[TBL] [Abstract][Full Text] [Related]
20. The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs.
Estey EH; Silberman L; Beran M; Andersson BS; Zwelling LA
Biochem Biophys Res Commun; 1987 Apr; 144(2):787-93. PubMed ID: 3034264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]